BeiGene to Present at Upcoming Investor Conferences
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company planning to rebrand as BeOne Medicines, has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Citizens JMP Hematology and Oncology Summit on December 2 at 1:00 p.m. ET and Citi's Global Healthcare Conference on December 5 at 9:30 a.m. ET. Live webcasts will be available on BeiGene's investor relations websites, with recordings accessible for 90 days after the events.
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), un'azienda globale nel campo dell'oncologia che prevede di rebrandizzarsi come BeOne Medicines, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. L'azienda parteciperà a conversazioni informali al Citizens JMP Hematology and Oncology Summit il 2 dicembre alle 1:00 p.m. ET e al Citi's Global Healthcare Conference il 5 dicembre alle 9:30 a.m. ET. Saranno disponibili webcast dal vivo sui siti web delle relazioni con gli investitori di BeiGene, con registrazioni accessibili per 90 giorni dopo gli eventi.
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), una empresa global de oncología que planea cambiar su nombre a BeOne Medicines, ha anunciado su participación en dos próximas conferencias para inversores. La compañía participará en charlas informales en el Citizens JMP Hematology and Oncology Summit el 2 de diciembre a la 1:00 p.m. ET y en la Citi's Global Healthcare Conference el 5 de diciembre a las 9:30 a.m. ET. Las transmisiones en vivo estarán disponibles en los sitios web de relaciones con los inversores de BeiGene, con grabaciones accesibles durante 90 días después de los eventos.
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), 전 세계적으로 활동하는 종양학 회사로 BeOne Medicines로 브랜드 변경을 계획하고 있는 BeiGene은 두 개의 투자자 회의에 참여할 것을 발표했습니다. 회사는 12월 2일 오후 1시(ET)에 열리는 Citizens JMP Hematology and Oncology Summit와 12월 5일 오전 9시 30분(ET)에 열리는 Citi's Global Healthcare Conference에서 화로 옆 대화에 참여할 예정입니다. BeiGene의 투자자 관계 웹사이트에서 라이브 웹캐스트를 이용할 수 있으며, 행사 후 90일 동안 녹화된 내용도 접근 가능합니다.
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), une entreprise mondiale en oncologie qui prévoit de se renommer BeOne Medicines, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise participera à des conversations informelles lors du Citizens JMP Hematology and Oncology Summit le 2 décembre à 13h00 ET et lors de Citi's Global Healthcare Conference le 5 décembre à 9h30 ET. Des webcasts en direct seront disponibles sur les sites web des relations investisseurs de BeiGene, avec des enregistrements accessibles pendant 90 jours après les événements.
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, das plant, sich in BeOne Medicines umzuorientieren, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird an informellen Gesprächen beim Citizens JMP Hematology and Oncology Summit am 2. Dezember um 13:00 Uhr ET und beim Citi's Global Healthcare Conference am 5. Dezember um 9:30 Uhr ET teilnehmen. Live-Webcasts werden auf den Investor Relations-Webseiten von BeiGene verfügbar sein, und Aufzeichnungen sind 90 Tage nach den Veranstaltungen zugänglich.
- None.
- None.
- Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET; and
- Citi’s Global Healthcare Conference on Thursday, December 5 at 9:30 a.m. ET
The live webcasts of these events can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241126305752/en/
Investors:
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media:
Kyle Blankenship
+1 667-351-5176
media@beigene.com
Source: BeiGene, Ltd.
FAQ
When is BeiGene (BGNE) presenting at the Citizens JMP Hematology Summit?
What is BeiGene's (BGNE) new planned company name?
How long will BeiGene's (BGNE) December 2023 investor conference webcasts be available?
Which stock exchanges is BeiGene (BGNE) listed on?
